The ALS Association today announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).
Departments, Centers, & Programs:
15 Parkman Street
Boston, MA 02114-3117
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My research activities are dedicated to the study and treatment of patients with Amyotrophic Lateral Sclerosis (ALS) and other neurological disorders. As Director of the MGH Neurological Clinical Research Institute and the Principal Investigator for the NINDS supported NeuroNEXT Clinical Coordinating center (www.neuronext.org), I design clinical trials to evaluate the safety and effectiveness of therapies that have shown promise in preclinical studies. In ALS, I co-founded an international consortium to test novel therapies in ALS, the Northeast ALS (NEALS) consortium. The NEALS consortium consists of over 128 clinical sites in the United States and Canada dedicated to performing joint academic led clinical trials in ALS.. We are leading several new trials in ALS. There is a critical need in neurology for highly trained clinical investigators who work collaboratively with basic scientists to develop new therapeutic strategies.
In 2019 we launched the Sean M. Healey & AMG Center for ALS at Mass General. This new Center is dedicated to accelerating therapy development and access to treatments for people with ALS. We are launching the first Platform Trial initiative in ALS where several treatments will be tested in one platform approach. This groundbreaking initiative will cut in half the time to develop treatments, increase by 67% ability of people to receive active treatment and cut costs of drug development by 33%. This approach, already successful in oncology, will revolutionize how treatments are developed in ALS. The Healey Center bring collaborators from around the world to work together to find treatments for people with ALS.
- Press Release
- Dec | 6 | 2019
Inaugural Mass General Hospital HEALEY Center international prize for innovation in ALS awarded at 2019 MND Meeting in Perth, Australia
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital awarded the inaugural annual Healey Center International Prize for Innovation in Amyotrophic Lateral Sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS.
- Press Release
- Jan | 22 | 2020
Sean M. Healey & AMG Center for ALS at Mass General receives “May Proceed” notice for three drugs in first ALS platform trial
The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS).
- Press Release
- Jul | 9 | 2019
One day after the launch of the new Sean M. Healey & AMG Center for ALS at Mass General on November 29 and 30, 2018, the Center’s scientific advisory council (SAC) held their first meeting in Palm Beach, Florida.
- Nov | 14 | 2018
Episode #14 of the Charged Podcast.
- May | 16 | 2019
Doctors have struggled for years to find an effective treatment for amyotrophic lateral sclerosis (ALS), in part because it varies greatly from patient to patient in terms of how quickly it progresses and the age of onset.